Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-03-13
2010-10-19
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S308000
Reexamination Certificate
active
07816324
ABSTRACT:
The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.
REFERENCES:
patent: 5212203 (1993-05-01), Shroot et al.
patent: 5929114 (1999-07-01), Domagala et al.
patent: 2005/0261346 (2005-11-01), Zhu et al.
Ahn, J.-M., et al., “A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning.” J. Med. Chem. (2001), 44:3109-3116.
Ahn, J.-M., et al., “Development of potent truncated glucagon antagonists.” J. Med. Chem. (2001), 44:1372-1379.
Ahn, J.-M., et al., “Peptidomimetics and peptide backbone modifications.” Mini-Reviews in Medicinal Chemistry (2002), 2:463-473.
Bulotta, et al., “ACultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1.” J. Mol. Endocrinol. (2002), 29:347-360.
Burgess, K., et al., “Solid-phase syntheses of β-turn analogues to mimic or disrupt protein-protein interactions”. Acc. Chem. Res. (2001), 34:826-835.
Cavaghan, M. K., et al., “Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.” J. Clin. Invest. (2000), 106:329-333.
Chang, L. L., et al., “Substituted imidazoles as glucagon receptor antagonists.” Bioorg. Med. Chem. Lett. (2001), 11:2549-2553.
Chapuis, H. P., et al., “Shorter puromycin analog synthesis by means of an efficient Staudinger-Vilarrasa coupling.” Tetrahedron (2006), 62:12108-12115.
Chen, D., et al., “A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.” Proc. Natl. Acad. Sci. U.S.A. (2007), 104:943-948.
Defronzo, R. A., et al., “Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.” Diabetes Care (2005), 28:1092-1100.
Drucker, D. J. et al., “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.” Lancet (2006), 368:1696-1705.
Edwards, C. M. B., et al., “Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.” Am. J. Physiol. Endocrinol. Metab. (2001), 281:E155-E161.
Egan, J. M., et al., “GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.” Diabetes/Metab. Res. Rev. (2003), 19:115-123.
Elbronds, B., et al., “Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.” Diabetes Care (2002), 25:1398-1404.
Ernst, J. T., et al., “Design and application of an α-helixmimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH-3/BcI-xL complex.” Angew. Chem. Int. Ed. (2003), 42:535-539.
Hoare, S. R. J., et al., “Mechanisms of peptide and nonpeptide ligand binding to class B G-proteincoupled receptors.” Drug Discovery Today (2005), 10:417-427.
Hruby, V. J., et al., “Design in topographical space of peptide and peptidomimetic ligands that affect behavior a chemist's glimpse at the mind-body problem.” Acc. Chem. Res. (2001), 34:389-397.
Jacoby, E., et al., “Biphenyls as potential mimetics of protein α-helix.” Bioorg. Med. Chem. Lett. (2002), 12:891-893.
Knudsen, L. B., et al., “Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.” J. Med. Chem. (2004), 47:4128-4134.
Knudsen, L. B., et al., “Small-molecule agonists for the glucagon-like peptide 1 receptor.” Proc. Natl. Acad. Sci. U.S. A. (2007), 104:937-942.
Kolterman, O. G., et al., “Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.” J. Clin. Endocrinol. Metab. (2003), 88:3082-3089.
Ling, A., et al., “Identification of alkylidene hydrazides as glucagon receptor antagonists.” J. Med. Chem. (2001), 44:3141-3149.
Madsen, P., et al., “Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.” J. Med. Chem. (2002), 45:5755-5775.
Mahato, R. I., et al., “Emerging trends in oral delivery of peptide and protein drugs.” Critical Reviews in Therapeutic Drug Carrier Systems (2003), 20:153-214.
Murphy, K. G.; “Nonpeptidic glucagon-like peptide 1 receptor agonists: A magic bullet for diabetes?” Proc. Natl. Acad. Sci. U.S.A. (2007), 104:689-690.
Neidigh, J. W., et al., “Exendin-4 and glucagon-likepeptide-1: NMR structural comparisons in the solution and micelle-associated states.” Biochemistry (2001), 40:13188-13200.
Oguri, H., et al., “Design and synthesis of a trans-fused polycyclic ether skeleton as an a-helix mimetic scaffold.” Tetrahedron Lett. (2005), 46:2179-2183.
Orner, B. P., et al., “Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an α-helix.” J. Am. Chem. Soc. (2001), 123:5382-5383.
Peczuh, M. W., et al., “Peptide and protein recognition by designed molecules.” Chem. Rev. (2000), 100:2479-2494.
Perry, T. A..,et al., “The glucagon-like peptides: a double-edged therapeutic sword?” Trends Pharmacol. Sci. (2003), 24:377-383.
Rickard, D. J., et al., “Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrow stromal cells.” Bone (2006), 39:1361-1372.
Runge, S., et al., “Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.” Br. J. Pharmacol. (2003), 138:787-794.
Souers, A. J., et al., “β-Turn mimetic library synthesis: scaffolds and applications.” Tetrahedron (2001), 57:7431-7448.
Stoffers, D. A., et al., “Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.” Diabetes (2000), 49:741-748.
Tibaduiza, E. C., et al., “A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain.” J. Biol. Chem. (2001), 276:37787-37793.
Toft-Nielsen, M. B., et al., “Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.” J. Clin. Endocrinol. Metab. (2001), 86:3853-3860.
Vilsboll, T., et al., “No reactive hypoglycaemia in type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.” Diabetic Med. (2001), 18:144-149.
Zander, M., et al., “Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell fuction in type 2 diabetes: a parallel-group study.” Lancet (2002), 359:824-830.
Zhang, B. B., et al., “New approaches in the treatment of type 2 diabetes.” Curr. Opin. Chem. Biol. (2000), 4:461-467.
International Search Report and Written Opinion for PCT/US2008/056920 dated Aug. 1, 2008.
International Search Report and Written Opinion for PCT/US2008/056918 dated Sep. 10, 2008.
Ahn, et al., “Facile synthesis of benzamides to mimic an alpha helix,” Tetrahedron Letters (2007), 48:3543-3547.
Konig, et al.,
Ahn Jung-Mo
Beinborn Martin
Board of Regents , The University of Texas System
Bradley Christina
Chalker Flores LLP
Flores Edwin S.
Singleton Chainey P.
LandOfFree
Composition and method for the treatment of diseases... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for the treatment of diseases..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for the treatment of diseases... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4233129